Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature.
Thrombotic microangiopathy (TMA) can be a late complication of bone marrow transplantation (BMT). A patient is described in whom the haemolytic uraemic syndrome developed 10 months after BMT and who died of E. coli sepsis while on maintenance haemodialysis. The literature is reviewed, regarding clinical presentation, incidence, pathogenesis and therapy. TMA can be observed, after an interval of 3-12 months, in about 6-26% of patients following BMT. Reported cases vary considerably in clinical severity, from mild presentations to severe TMA with high mortality rates despite intensive therapy. Important pathogenetic roles are ascribed to the conditioning total body irradiation and the use of cyclosporin A, but other factors may be involved as well. Next to supportive therapy, plasma exchange and the use of ACE inhibitors may be of value in treating BMT-associated TMA.
Verburgh
C A
CA
Department of Nephrology, University Hospital Leiden, Leiden, The Netherlands.
Vermeij
C G
CG
Zijlmans
J M
JM
van Veen
S
S
van Es
L A
LA
D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D016572:Cyclosporine / Q000009:adverse effects; D004927:Escherichia coli Infections / Q000150:complications; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000150:complications / Q000209:etiology* / Q000628:therapy; D006801:Humans; D008875:Middle Aged; D018805:Sepsis / Q000150:complications; D013927:Thrombosis / Q000150:complications / Q000209:etiology; D014916:Whole-Body Irradiation / Q000009:adverse effects
D016572:Cyclosporine